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Background: Japanese encephalitis virus (JEV) has a significant impact on public health. An estimated three billion
people in ‘at-risk’ regions remain unvaccinated and the number of unvaccinated individuals in certain Asian
countries is increasing. Consequently, there is an urgent need for the development of novel therapeutic agents
against Japanese encephalitis. Nitazoxanide (NTZ) is a thiazolide anti-infective licensed for the treatment of parasitic
gastroenteritis. Recently, NTZ has been demonstrated to have antiviral properties. In this study, the anti-JEV activity
of NTZ was evaluated in cultured cells and in a mouse model.
Methods: JEV-infected cells were treated with NTZ at different concentrations. The replication of JEV in the
mock- and NTZ-treated cells was examined by virus titration. NTZ was administered at different time points of JEV
infection to determine the stage at which NTZ affected JEV replication. Mice were infected with a lethal dose of JEV
and intragastrically administered with NTZ from 1 day post-infection. The protective effect of NTZ on the
JEV-infected mice was evaluated.
Findings: NTZ significantly inhibited the replication of JEV in cultured cells in a dose dependent manner with 50%
effective concentration value of 0.12 ± 0.04 μg/ml, a non-toxic concentration in cultured cells (50% cytotoxic
concentration = 18.59 ± 0.31 μg/ml). The chemotherapeutic index calculated was 154.92. The viral yields of the
NTZ-treated cells were significantly reduced at 12, 24, 36 and 48 h post-infection compared with the mock-treated
cells. NTZ was found to exert its anti-JEV effect at the early-mid stage of viral infection. The anti-JEV effect of NTZ
was also demonstrated in vivo, where 90% of mice that were treated by daily intragastric administration of 100 mg/
kg/day of NTZ were protected from a lethal challenge dose of JEV.
Conclusions: Both in vitro and in vivo data indicated that NTZ has anti-JEV activity, suggesting the potential
application of NTZ in the treatment of Japanese encephalitis.
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Nitazoxanide (2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide)
(NTZ) (Figure 1) is a thiazolide anti-infective, originally li-
censed in the United States (Alinia; Romark Laboratories,
Tampa, FL, USA), for the treatment of parasitic enteritis
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reproduction in any medium, provided the orin children and adults [1-3]. The antiviral properties of
NTZ were discovered during the treatment of crypto-
sporidiosis in patients with acquired immune deficiency
syndrome [4]. Recently, clinical trials have proven the
antiviral effectiveness of NTZ in treating rotavirus
gastroenteritis in young children, and rotavirus ancd
norovirus gastroenteritis in adults [5,6]. In addition,
NTZ has been demonstrated to have antiviral properties
against hepatitis B virus (HBV), hepatitis C virus (HCV)
and human-, avian- and canine-lineage influenza virus
[7-10], suggesting that NTZ is a new class of broad-. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structure of nitazoxanide (NTZ).
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is undergoing phase II clinical trials as a combinatorial
drug in the treatment of chronic hepatitis C [12].
The mechanism of activity of NTZ against non-viral an-
aerobic microorganisms is attributed to its interference
with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-
dependent electron transfer reactions, which are essential
for anaerobic energy metabolism [13]. By contrast, the
mechanisms that underlie the antiviral activity of NTZ
are not well understood. NTZ has been described to
induce PKR (double-stranded-RNA-activated protein
kinase) phosphorylation, which leads to the elevation
of phosphorylated eIF2α eukaryotic translation initi-
ation factor 2 alpha, an antiviral intracellular protein,
in HCV-infected cells [14]. While in influenza virus-
infected cells, NTZ prevents the maturation of viral
hemagglutinin (HA) protein possibly by blocking HA
trafficking between the endoplasmic reticulum and the
Golgi complex [9].
Japanese encephalitis (JE), previously known as Japanese
B encephalitis, is caused by Japanese encephalitis virus
(JEV), an enveloped arbovirus of the Flavivirus genus in
the family Flaviviridae. JE is most prevalent in Southeast
Asia and the Far East, and domestic pigs and wild birds
are the natural reservoirs of JEV. Transmission of JEV to
humans, which occurs mainly via the bite of infected mos-
quitoes, may cause severe symptoms typically including
fever, headache and other incapacitating manifestations
[15]. Although two types of JEV vaccines have long been
used, JE still causes 10,000-15,000 encephalitic deaths
throughout the world annually [16]. As an arthropod-
borne infectious disease, JE has recently spread its geo-
graphic footprint into previously non-endemic areas [17].
An estimated three billion people in ‘at-risk’ regions re-
main unvaccinated and the number of unvaccinated indi-
viduals in certain Asian countries is increasing because of
population growth, intensified rice farming, pig rearing,
climate change and the lack of vaccination programs and
surveillance [17]. Consequently, there is an urgent need
for the development of novel therapeutic agents againstJE. Although attempts to develop new antiviral drug
are ongoing [18], no effective antiviral drug against JE
is available at present.
JEV and HCV belong to the family Flaviviridae, and
NTZ inhibits the replication of HCV both in cell culture
[14] and in patients [12]. The emergence of NTZ with
broad-spectrum antiviral properties prompted us to evalu-
ate its antiviral activity against JEV. We found that
NTZ inhibited the replication of JEV in cultured cells
and reduced mortality in mice challenged with a lethal
dose of JEV.
Results
NTZ inhibits the JEV-induced cytopathic effect (CPE)
To measure the cytotoxicity of NTZ to baby hamster kid-
ney (BHK-21) cells that are susceptible to JEV infection,
BHK-21 cells were treated with NTZ at various concentra-
tions ranging from 0.1 to 32 μg/ml and incubated for 48 h.
The cell viability was analyzed by a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The
50% cytotoxic concentration (CC50) that reduced the
proliferation of exponentially growing BHK-21 cells by
50% was 18.59 ± 0.31 μg/ml (Figure 2A). It is known
that replication of JEV results in the formation of a CPE
in BHK-21 cells. To determine whether NTZ interferes
with the formation of JEV-induced CPE, NTZ at con-
centrations from 0.1 to 10 μg/ml was added to BHK-21
cells after a 1 h JEV adsorption period and the cells were
incubated for 48 h. The effect of NTZ on the inhibition
of JEV-induced CPE formation was visualized under a
light microscope. As shown in Figure 2B, a severe CPE
was visible in JEV-infected cells that were treated with
dimethyl sulfoxide (DMSO) (JEV + DMSO panel), while
in the JEV-infected cells that were treated with NTZ
(JEV + NTZ panels), the formation of CPE was reduced
by treatment with NTZ in a dose-dependent manner.
No CPE was observed in the mock-infected cells that
were treated with NTZ (Mock + NTZ panel) or DMSO
(Mock + DMSO panel). Although treatment of the mock-
infected cells with NTZ or DMSO led to a slight morpho-
logical change in cells, these changes were quite different
from the JEV-induced CPE. These data implied that NTZ
is able to inhibit the replication of JEV in BHK-21 cells.
NTZ inhibits the replication of JEV in BHK-21 cells
To determine whether NTZ inhibits the replication of
JEV, the JEV-infected BHK-21 cells were treated with NTZ
at various concentrations ranging from 0.01 to 10 μg/ml
for 48 h. The JEV-infected cells that were parallelly treated
with DMSO were used as a control. The titers of virus
present in the cell lysates and supernatants were deter-
mined by a plaque assay and the reduction in the virus
titer was calculated. An inhibition curve of JEV in the
presence of a serial dilutions of NTZ is shown in
Figure 2 Analysis of the effect of NTZ on the formation of JEV-induced CPE. (A) BHK-21 cells were treated with the indicated concentrations
of NTZ for 48 h and the cytotoxicity of NTZ was analyzed by MTT assay. DMSO-treated cells were used as a control. The data are means with SD
from three independent experiments. (B) BHK-21 cells were infected with JEV at a MOI of 0.001. After a 1 h adsorption period, the cells were
treated with NTZ at the indicated concentrations and incubated for 48 h. The JEV-induced CPE was examined under a light microscope.
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NTZ was 0.12 ± 0.04 μg/ml. The chemotherapeutic
index (CTI) calculated as a ratio СC50/EC50 was 154.92.
To further characterize the antiviral property of NTZ,
the JEV-infected BHK-21 cells were treated with NTZ at a
concentration of 3 μg/ml and incubated for the indicated
times (Figure 3B). The NTZ concentration of 3 μg/ml was
chosen because at this concentration NTZ cytotoxicity
had no significance and approximately 100% of virus titer
reduction was observed (Figure 2A and Figure 3A). The
JEV-infected cells that were parallelly treated with DMSO
were used as a control. The titers of virus in the cells and
in the supernatants were measured by a plaque assay, re-
spectively. In the DMSO-treated cells, the infectious pro-
geny viruses, both in the cells and the supernatants, were
detectable from 12 h post-infection, while they were not
detectable until 24 h post-infection in the NTZ-treated
cells. The viral yields from the NTZ-treated cells were sig-
nificantly reduced at 12, 24, 36 and 48 h post-infection
compared with the DMSO-treated cells (Figure 3B). A de-
cline in viral titer was observed 60 h post-infection in the
DMSO-treated cells. This decrease was probably due toserious necrocytosis/apoptosis of the cells induced by
rapid viral replication, which contributes to the decline
in virus infectivity in addition to temperature that influ-
ences the infectivity and stability of extracellular vi-
ruses. The number of intracellular RNA copies of the
viral C gene in the NTZ-treated and DMSO-treated
cells was determined by a quantitative real-time reverse
transcription-polymerase chain reaction (qRT-PCR). As
shown in Figure 3C, treatment of JEV-infected cells with
3 μg/ml NTZ significantly reduced the number of copies
of viral RNA compared with the DMSO-treated cells.
The inhibitory effect of NTZ on the replication of
JEV was further confirmed at viral protein level. The
expression of viral NS3 protein in the NTZ-treated and
DMSO-treated cells was detected by western blot and
immunofluorescence analysis. As shown in Figure 4A,
the abundance of viral NS3 protein in the NTZ-treated
cells (JEV + NTZ) at 24 h post-infection was remarkably
less than that in the DMSO-treated cells (JEV + DMSO).
In the immunofluorescence analysis, although the num-
bers of NS3-positive cells (green fluorescence) among
the NTZ-treated cells (JEV + NTZ panels) were similar
Figure 3 Analysis of the effect of NTZ on JEV replication in BHK-21 cells. BHK-21 cells were infected with JEV at a MOI of 0.001 and treated
with NTZ at the indicated concentrations. (A) The cells were incubated for 48 h and harvested for virus titration. The reduction in virus titer was
calculated and plotted. The x-axis is in a base 2 logarithmic scale. (B) The JEV-infected cells were treated with NTZ at 3 μg/ml and incubated for
the indicated times. The virus titers in the cells and supernatants were determined by a plaque assay, respectively. (C) The JEV-infected cells were
treated with NTZ at 3 μg/ml and incubated for the indicated times. The number of RNA copies of viral C gene in the cells was determined by qRT-PCR.
The data are means with SD from three independent experiments. *, p < 0.05 compared with the DMSO-treated cells. hpi, hours post-infection.
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DMSO panels), the strength of the fluorescence signals
in the NTZ-treated cells was remarkably lower than
that in the DMSO-treated cells (Figure 4B and 4C).
Taken together, these data suggested that NTZ inhibited
the replication of JEV.
NTZ inhibits JEV replication at the early-mid stage of viral
infection
To determine the stage at which NTZ affected JEV repli-
cation, NTZ at a concentration of 3 μg/ml was added
into BHK-21 cells at different time points before viral in-
fection (Pre 10 h, Pre 5 h and Pre 2 h), during viral ad-
sorption (Ad 0 h), at the early stage of viral infection
(Post 1 h and 2 h), at the mid stage of viral infection
(Post 5 h) and at the late stage of viral infection (Post
10 h) (Figure 5A). The viral titers in each group were
assayed 24 h post-infection. As shown in Figure 5B, pre-
treatment of cells with NTZ up to 10 h before viral in-
fection had no effect on JEV replication (Pre 2 h, 5 h
and 10 h). Moreover, NTZ treatment only during the
adsorption period did not inhibit virus replication(Figure 5B, Ad 0 h), indicating that NTZ was not
directly affecting viral infectivity, adsorption and entry
into target cells. In contrast, NTZ treatment initiated at
the early stage of viral infection (Post 2 h) was the most
effective in inhibiting virus replication (Figure 5B, Post
2 h). NTZ treatment started at the mid stage of viral in-
fection (Post 5 h) was relatively less effective, but still
able to significantly inhibit virus replication (Figure 5B,
Post 5 h), whereas NTZ was ineffective when adminis-
tered at the late stage of viral infection (Figure 5B, Post
10 h). Taken together, these data suggested that NTZ
inhibited JEV replication in vitro at the early-mid stage
of viral infection.
NTZ reduces the mortality of mice challenged with a
lethal dose of JEV
To evaluate the protective effect of NTZ on mice chal-
lenged with a lethal dose of JEV, NTZ was administered
intragastrically at the indicated doses from 1 day post-
infection, daily, for up to 25 days. The mice that were in-
fected with JEV and received a placebo (DMSO) treatment
(group JEV +DMSO) started to show the clinical signs of
Figure 4 Detection of viral NS3 protein in NTZ-treated cells. BHK-21 cells were infected with JEV at a MOI of 0.001 and treated with NTZ at
3 μg/ml. The cells were harvested at 24 or 60 h post-infection (hpi). (A) The same amount (20 μg) of cell lysate was loaded in each lane. The
expression of viral NS3 protein was examined by western blot. (B) The viral NS3 protein (green fluorescence) was detected at 24 hpi by
immunofluorescence analysis. The cells were also stained for DNA with 4′, 6′-diamidino-2-phenylindole (DAPI, blue fluorescence). The Merge
panels show the superimposed images. (C) Fluorescence intensity of NS3 and DAPI was quantified using the software ImageJ. The ratio of
fluorescence intensity between NS3 and DAPI was calculated and plotted. The data are means with standard errors from three independent
experiments. *, p < 0.01 between the groups tested.
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piloerection, body stiffening and whole body tremors,
from 5 days post-infection, and all mice (10/10 mice) died
within 9 days post-infection. In contrast, the mice that
were infected with JEV and received NTZ treatment
(group JEV +NTZ, 100 mg/kg/day) showed the clinical
signs of JE from 11 days post-infection, among these 10
mice, 1 died within 12 days post-infection and 9 survived
the experimental period (25 days) (Figure 6A). The NTZ-
mediated protection appeared to be dose dependent, as
the infected mice receiving 50 mg/kg/day, 75 mg/kg/day
and 100 mg/kg/day NTZ led to 30%, 70% and 90% mice
survival, respectively (Figure 6A). These data suggested
that NTZ treatment reduced the mortality of JEV-infected
mice and protected mice from a lethal dose challenge of
JEV. The mice that were mock-infected with JEV and re-
ceived NTZ treatment (group Mock +NTZ) showed no
detectable signs of abnormal behavior, similarly to the
mice that were mock-infected and received DMSO
treatment (group Mock + DMSO) (Figure 6A). Analysis
of JEV titers in the brain samples from the experimental
mice indicated that NTZ treatment significantly reducedthe virus load in the brain from the group JEV +NTZ
compared with that from group JEV +DMSO (Figure 6B).
The brain samples from the experimental mice were
examined for the presence of viral NS3 protein by im-
munohistochemistry. The viral NS3 protein was stained
as brown deposits in the cytoplasm of neuronal cells
(Additional file 1, arrowed cells). The brain sections
from the JEV +DMSO group of mice showed remarkably
higher numbers of NS3-stained positive cells than the sec-
tions from the JEV +NTZ group. No NS3-stained positive
cells were detected in the sections from the Mock +NTZ
or Mock + DMSO groups of mice.
Discussion
NTZ is an anti-infective licensed in the United States for
the treatment of parasitic gastroenteritis [1-3]. This drug
has been demonstrated to be safe and effective even when
administered over a year [8]. NTZ has been considered to
be a new class of broad-spectrum antiviral drugs [11].
Given the fact that there is an urgent need for an effective
drug against JEV and that there is currently no effective
antiviral agent available for the treatment of JE, we tested
Figure 5 Inhibition of JEV replication in vitro by NTZ at the early-mid stage of viral infection. (A) Schematic representation of the
experimental design. BHK-21 cells were treated with 3 μg/ml NTZ at the indicated times before infection (Pre 10 h, Pre 5 h and Pre 2 h), during
the adsorption period (Ad 0 h), and after the adsorption period (Post 1 h, Post 2 h, Post 5 h and Post 10 h). (B) The virus titer in each group was
determined 24 h post-infection by a plaque assay and plotted. The data are means with SD from three independent experiments. *, p < 0.05
between the groups tested.
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mouse models. We found that NTZ was able to inhibit
the replication of JEV in BHK-21 cells in a dose-
dependent manner (Figure 2 and Figure 3). NTZ also
reduced the mortality of mice challenged with a lethal
dose of JEV (Figure 6).
We observed that NTZ significantly inhibited the rep-
lication of JEV in BHK-21 cells in a dose dependent
manner with EC50 value of 0.12 ± 0.04 μg/ml (Figure 3A),
whereas the EC50 for influenza A virus (PR8 strain) is
1.0 μg/ml [9]. As a new class of broad-spectrum antiviral
drugs, NTZ has been speculated to target host functions
that are essential for viral replication [9,14]. In the case
of HCV infection, NTZ increases eIF2α phosphorylation,
a modification known to mediate host antiviral defenses
[14]. However, in the case of influenza virus infection,
NTZ prevents the maturation of viral HA possibly
by blocking HA trafficking between the endoplasmic
reticulum and the Golgi complex [9]. In our study, we
found that NTZ exerted its antiviral activity in vitro at the
early-mid stage of viral infection (Figure 5), indicating that
NTZ does not affect JEV infectivity, adsorption or entryinto target cells. However, the exact mechanism of how
NTZ inhibited JEV replication needs to be further
explored.
Although there are currently no effective drugs available
for the treatment of JE, attempts to develop new antiviral
drugs are ongoing. For example, peptide-conjugated phos-
phorodiamidate morpholino oligomers (PPMOs) have re-
cently been reported which are antisense agents targeting
the 3′ cyclization sequence of JEV, they have been shown
to significantly inhibit the replication of JEV in cells and in
a mouse model [19]. In comparison with previously pro-
posed therapeutic agents, such as PPMOs, siRNA [20,21],
arctigenin [22] and isatis indigotica extracts [23], NTZ is a
licensed, safe drug and is therefore a promising candidate
for use as an anti-JEV therapeutic agent. Further studies
into the mechanism of action and the efficacy of NTZ are
currently underway in our laboratory.
Conclusions
The anti-JEV activity of NTZ was evaluated in cultured
cells and in a mouse model. NTZ significantly inhibited
the replication of JEV in BHK-21 cells in a dose dependent
Figure 6 Analysis of the protective effect of NTZ on mice challenged with a lethal dose of JEV. Mice (10 mice/group) were infected
intraperitoneally with 6×104 PFU of JEV and treated with NTZ from 1 day post-infection. NTZ was administered daily at the indicated doses (50,
75 or 100 mg/kg/day) by intragastric administration for up to 25 days. (A) The mice were monitored daily for morbidity and mortality. The daily
survival rates were plotted. *, p < 0.0001 between the group JEV + DMSO and group JEV + NTZ tested by the Gehan-Breslow-Wilcoxon test.
(B) The brain tissues were collected from the mice euthanized on the indicated days after JEV infection. The virus titer in each group was
determined by a plaque assay and plotted. The data are means with SD from three independent experiments. *, p < 0.05 compared with the
NTZ-treated groups.
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found to exert its anti-JEV effect in vitro at the early-mid
stage of viral infection. The anti-JEV effect of NTZ was
also demonstrated in vivo, where 90% of mice that were
treated with NTZ were protected from a lethal challenge
dose of JEV. Both our in vitro and in vivo data indicated
that NTZ has anti-JEV activity, suggesting the potential
application of NTZ in the treatment of JE.
Materials and methods
Virus, cells and NTZ administration
JEV strain (SH-JEV01) [24] was grown in 3-day-old BALB/c
mice and titrated by a plaque assay using BHK-21 cells
as described below. BHK-21 (C-13, ATCC number
CCL-10) cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) at 37°C in an atmosphere containing
5% CO2.
NTZ (purity ≥ 98%) was purchased from Sigma–Aldrich
(Sigma, St. Louis, MO, USA) and was dissolved in culture-grade DMSO (Sigma) at a concentration of 50 μg/μl.
NTZ solution was added immediately after a 1 h ad-
sorption period and was kept in the culture medium for
the duration of the experiment, unless specified other-
wise. Controls received equal amounts of DMSO (final
concentration ≤ 0.06%), which did not affect cell viability
or virus replication.
Cytotoxicity test
BHK-21 cells were seeded in a 96-well plate at a density of
5 × 103 cells per well. Following 24 h of incubation, the
cells were treated with NTZ at various concentrations ran-
ging from 0.1 to 32 μg/ml at 37°C for 48 h. Cells treated
with DMSO alone were used as a control. The cellular
toxicity of NTZ was assessed using MTT assay (Roche,
Mannheim, Germany). Cell viability was calculated as a
percentage of the total number of viable DMSO-treated
control cells. The CC50, which is defined as the concen-
tration that inhibits the proliferation of exponentially
growing cells by 50%, was calculated as described [25].
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BHK-21 cells were seeded at 1 × 106 cells per well on
six-well plates. Cultures were inoculated with JEV at a
multiplicity of infection (MOI) of 0.001 when the cells
reached approximately 80–90% confluence. The inocu-
lum was removed following a 1 h incubation period, and
cells were washed twice with phosphate-buffered saline
(PBS). Cultures were further incubated in DMEM with
2% FBS for the indicated times. Following incubation,
the cells and the culture supernatants were collected
and stored at −70 °C until further use.
The plaque assay for JEV infectivity was performed as
described [26]. Briefly, BHK-21 cells were seeded in six-
well plates and incubated overnight. The medium was
replaced with PBS containing serially diluted JEV. The
cells were incubated at 37°C for 4 h. After the adsorp-
tion period, the inoculum was replaced with DMEM
containing 2% FBS and 1% low-melting-point agarose
and incubated for 5 days. On 5 days post-inoculation,
the cells were fixed with 1% formaldehyde overnight to
penetrate the agarose. The cells were stained with 0.05%
neutral red for 1 h at room temperature after removing
the overlaid agarose. The plaques were then counted,
and infectivity was expressed as plaque forming units
(PFU)/ml.
qRT-PCR
Total RNA was isolated from cells using the QIAamp
viral RNA minikit (Qiagen, Hilden, Germany), according
to the manufacturer’s protocol. One microgram of total
RNAs isolated from JEV-infected cells was used for syn-
thesis of cDNA using AMV reverse transcriptase (TaKaRa,
Otsu, Japan). The qRT-PCR for analysis of JEV replication
was performed using Premix Ex Taq™ (TaKaRa), according
to the manufacturer’s protocol. Briefly, reactions were pre-
pared in 20 μl containing 1 μl of cDNA, 10 μl of SYBR
Premix Ex Taq™ (2×), and 0.2 μM of specific primers. The
amplification parameters were: 2 min at 95°C, followed by
40 cycles of 15 sec at 95°C, and 60 sec at 60°C. The se-
quences of the primers used to amplify 181 bp of the gene
encoding core protein C (C) of JEV were: 5′-AAAAA
CCAGGAGGGCCCGG-3′(nucleotide position 103–121)
and 5′-TTGGTCGGGGCTAATGCTGTAAA-3′(nucleo-
tide position 283–261). These primers were designed
according to the sequence of JEV strain SA14 (GenBank
accession No. U14163). Quantification was achieved by
relating the cycle threshold (Ct) value of virus to the Ct
value on a standard curve of a measured number of
copies of the JEV C gene cloned into pMD18-T vector
which the resulting plasmid was named pM-C. The
quantitative standard curve for the determination of JEV
RNAs copy number was created by quantitative real-time
PCR of standard plasmid pM-C preparations at serial dilu-
tions of 106, 105, 104, 103, 102 and 101 copies/μl. Thenumber of JEV RNAs copies was calculated by Eppendorf
Mastercycler ep realplex 2.2 software automaticlly.
Analysis of the antiviral effect of NTZ in BHK-21 cells
BHK-21 cells in six-well plates were infected with JEV at
a MOI of 0.001. After a 1 h adsorption period, the cells
were treated with NTZ at concentrations ranging from
0.01 to 10 μg/ml and incubated at 37°C for 48 h or the
indicated times. The virus yield was determined by a
plaque assay and qRT-PCR. The reduction in the virus
titer was calculated as follows:% virus titer reduction =
[1-(PFUJEV+NTZ/PFUJEV+DMSO)] × 100. The EC50 that is
defined as the concentration offering 50% inhibition of
viral yield in cells was calculated as described [25].
Western blot, immunofluorescence and
immunohistochemistry analysis
The expression of viral NS3 in JEV-infected cells was
examined by western blot and immunofluorescence
analysis as described [24,27]. The fluorescence intensity
of cells was quantified using the software ImageJ that is
a Java-based image processing program developed at
the National Institutes of Health (http://rsbweb.nih.gov/
ij/index.html). The immunohistochemistry for analysis of
viral NS3 in brain of JEV-infected mice was performed as
described [24].
Analysis of the antiviral effect of NTZ in a mouse model
Three-week old female Chinese Kunming mice (12–14 g
body weight) were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd (Shanghai, China) and were
randomly divided into six groups (10 mice/group). Group
JEV +NTZ was infected with JEV and received NTZ treat-
ment (50, 75 or 100 mg/kg/day). Group JEV +DMSO was
infected with JEV and received a placebo (DMSO) treat-
ment. Group Mock +NTZ was mock-infected with JEV
and received NTZ treatment. Group Mock + DMSO was
mock-infected with JEV and received a placebo (DMSO)
treatment. For infection, mice were infected intraperitone-
ally with 6×104 PFU of JEV (containing 50 × LD50 of JEV).
For NTZ treatment, NTZ was dissolved in DMSO and ad-
ministered intragastrically by gavage, in which a feeding
needle was introduced into the esophagus and NTZ was
delivered directly into the stomach. NTZ was tested at a
total dose of 50, 75 or 100 mg/kg/day, and was consecu-
tively administered from 1 day post-infection, daily, for up
to 25 days. The mice were monitored daily for morbidity
and mortality. The mice that showed neurological signs
were euthanized according to the Guidelines on the
Humane Treatment of Laboratory Animals (Ministry
of Science and Technology of the People’s Republic of
China, Policy No. 2006 398). The animal experiments
were in compliance with the Guidelines on the Humane
Treatment of Laboratory Animals (Policy No. 2006 398)
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Use Committee at the Shanghai Veterinary Research
Institute, Chinese Academy of Agricultural Science.
Statistical analysis
All experiments were carried out in triplicate. The mea-
sured values are expressed as the means with standard
deviations (SD). Significance was analyzed using the
Student’s t-test or the Gehan-Breslow-Wilcoxon test.
Value of p < 0.05 was considered significant.
Additional file
Additional file 1: The brain tissues were collected from the mice
euthanized on 9 days after JEV infection and were stained
immunohistochemically for viral NS3 protein, which stains as
brown deposits in the cytoplasm of neuronal cells (arrowed
cells). JEV+NTZ, mice were infected with JEV and received NTZ (100
mg/kg/day) treatment. JEV+DMSO, mice were infected with JEV and
received a placebo (DMSO) treatment. Mock+NTZ, mice were
mock-infected with JEV and received NTZ (100 mg/kg/day) treatment.
Mock+DMSO, mice were mock-infected with JEV and received DMSO
treatment. Bar, 100 μm.
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